[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648270":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":10,"responsibleParty":21,"collaborators":23,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":10,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":43,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"Aeterna Medical Solutions SL","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Reference Monotherapy",null,"Finerenone",{"label":13,"type":10,"description":14,"interventionNames":10},"Early Combo Strategy","Concomitant combination of finerenone and empagliflozin",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Carlos Escobar Cervantes","CONTACT","+34620210491","escobar_cervantes_carlos@hotmail.com",{"type":22,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[24],{"name":25,"class":26},"Bayer Hispania, S.L","UNKNOWN","100648270","evaluation-of-the-risk-of-heart-failure-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus-100648270",false,"NCT07719621","Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus","Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D","Inclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Patients with chronic kidney disease (eGFR 30-90 ml\u002Fmin\u002F1.73 m²)\n* Persistent albuminuria (UACR 100-5000 mg\u002Fg)\n* Type 2 diabetes mellitus (T2D) under stable blockade of the renin-angiotensin system (ACEi\u002FARB)\n\nExclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Participants with type 1 diabetes (T1D).\n* Participant with hepatic insufficiency classified as Child-Pugh C.\n* Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.","ALL",{"count":36,"type":37},50000,"ESTIMATED","OBSERVATIONAL","The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* How many events of heart failure, heart failure hospitalizations, and cardiovascular death happen in each group?\n* How do serious kidney problems progress in each of the groups?\n\nResearchers will compare reference therapy (finerenone) with a combination of finerenone and empagliflozin.\n\nThere will not be human participants in this study. With the help of artificial intelligence, researchers will recreate a large population of people with chronic kidney disease and type 2 diabetes mellitus. Data on their disease, treatment, and laboratory parameters will be based on and simulated using real data from previous clinical trials conducted with real participants.",[41,42],"CKD - Chronic Kidney Disease","Diabetes Mellitus Type 2",[44,42,45,46],"Chronic Kidney Disease","finerenone","empagliflozin","NOT_YET_RECRUITING","2026-08-17",{"date":50,"type":51},"2026-08-19","ACTUAL",{"date":53,"type":37},"2026-09",{"date":55,"type":37},"2026-11",{"name":5,"class":6}]